Elanco Animal Health Inc. (ELAN) is a renowned global animal health company that develops, manufactures, and markets products for companion and food animals. Incorporated in 2018 and headquartered in Greenfield, Indiana, Elanco is committed to improving animal health. Through innovative products and services, it ensures the well-being of pets and livestock, indirectly benefiting humans who depend on these animals for companionship, food, and other necessities.
Elanco initially started as a division of pharmaceutical giant Eli Lilly and Company. Following its spinoff and its initial public offering, it became an independent entity and competes with leading manufacturers in the animal health sector. Elanco's range of products is extensive, covering vaccines, nutritional supplements, parasite control, therapies, disease management, and animal-only antibiotics.
Elanco's mission is to improve the lives of animals, which in turn enhances the lives of the people who care for them. The corporation operates in more than 90 countries, and its dietary supplements and veterinary medicines are sold in over 100 countries, making it a truly global company.
At the heart of Elanco's operations is innovation. It continuously works to develop new products and improve its existing ones, carry out disease control research, and promote sustainable livestock production. From enhancing animal performance to preventing and controlling diseases that threaten animal populations, Elanco’s innovative solutions continue to make a profound impact worldwide.
Concerning corporate responsibility, Elanco has a comprehensive approach that includes contributing to global food security, promoting responsible antibiotic use, and reducing its environmental footprint. At the company's core are its four guiding principles: food and companionship, enriching life, responsibility, and innovation.
Financially, Elanco has positioned itself as one of the largest players in the animal health industry. Notably, in 2020 Elanco completed the acquisition of Bayer Animal Health, showcasing the company’s strategic expansion plans. This acquisition has established Elanco as a leader in the pet health industry, bolstering its market presence.
In conclusion, Elanco Animal Health Inc. (ELAN) is a pioneering company, transforming the lives of animals and people around the globe. With its dedication to innovation, responsibility, and quality healthcare products, Elanco is poised to continue leading the way in animal health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Elanco Animal Health recently held an Employer Spotlight event at MoWest, inviting students, especially those in Engineering, Chemistry, Biology, and Supply Chain Management, to learn about their summer 2027 internship opportunities. The company, known for its innovative animal health solutions, is looking to fill six intern positions, emphasizing teamwork and a readiness to learn. Interns will gain hands-on experience and could potentially secure full-time employment, with applications due by November 15, 2026.
Elanco Animal Health has appointed Jamie Preston, MHA, as its new executive vice president and chief people officer, effective November 3, 2026. The Animal Health Institute (AHI) announced Andrew Bailey, JD, as vice president of government affairs and public policy, starting November 16, 2026. Additionally, the University of Maryland Eastern Shore School of Veterinary Medicine (UMES SVM) has named Paul Nader, DVM, as associate professor of anatomy, ahead of its inaugural DVM class in summer 2027.
Elanco Animal Health (NYSE: ELAN) reported better-than-expected third-quarter financial results, driven by strong demand and higher prices for its pet health products, particularly Zenrelia and Credelio Quattro. The company exceeded analyst estimates for both earnings and sales and raised its full-year 2026 guidance, expecting mid-single-digit organic constant currency revenue growth and low-double-digit adjusted EPS growth heading into 2027. This positive outlook is fueled by significant market share gains and increased clinic penetration for its key innovative products.
Elanco Animal Health Incorporated (NYSE: ELAN) released findings from its latest U.S. consumer research, indicating that pet owners prioritize pet health spending despite economic pressures, with 93% maintaining or increasing spending in the last three months. The survey also revealed a shift in pet medication purchasing towards omnichannel convenience, while veterinarians remain the primary trusted authority. Additionally, the research suggests strong future demand for pet adoption.
Elanco Animal Health reported strong third-quarter 2026 financial results, with reported revenue up 11% and organic constant currency growth of 9%, driven by increased demand in International and U.S. Pet Health. The company achieved significant gross margin expansion, reduced net leverage below three times, and raised its full-year innovation revenue target to $1.275 billion. Elanco also reiterated its 2027 guidance for mid-single-digit revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth, highlighting continued momentum from key product launches like Zenrelia and Credelio Quattro.
Elanco Animal Health (NYSE:ELAN) reported strong third-quarter 2026 results, with revenue up 11% to $1.265 billion and a net income of $18 million, a significant improvement from a loss in the prior year. The company saw growth across both its Pet Health and Farm Animal segments, leading it to increase its full-year 2026 revenue and adjusted EPS guidance, along with its innovation revenue target. Elanco remains focused on product innovation and operational efficiency to drive future growth.
Elanco Animal Health announced strong third-quarter 2026 results, reporting revenue of $1.265 billion, an 11% increase year-over-year with 9% organic constant currency growth. The company also raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS, and achieved a net leverage ratio of 2.9x Adjusted EBITDA. This performance was driven by accelerated price growth, organic revenue growth in Pet Health and Farm Animal segments, and gross margin expansion, leading to increased capital allocation flexibility.
Elanco (NYSE: ELAN) exceeded Wall Street's Q3 2026 revenue and adjusted EPS estimates, reporting an 11.3% year-on-year revenue increase to $1.27 billion and an adjusted profit of $0.27 per share. The company also provided better-than-expected revenue guidance for Q4 2026 and raised its full-year adjusted EPS guidance. Following the announcement, Elanco's shares surged 7.4%.
Elanco Animal Health Incorporated (NYSE:ELAN) saw its shares climb 7.6% after reporting stronger-than-expected third-quarter 2026 earnings and revenue. The company's adjusted earnings of $0.27 per share and revenue of $1.26 billion both surpassed analyst estimates, driven by growth in its Pet Health and Farm Animal segments. Consequently, Elanco raised its full-year 2026 financial guidance for both adjusted earnings and revenue.